Nils Eckardt, Vice President Medical Affairs, Europe, shares BeiGene’s innovative vision for patients.

A short summary describing an antibody targeting TIM-3 which enhances T cell activity and NK-cell tumor cytotoxicity and may help overcome anti-PD-1 resistance in solid tumors.

Chat with BeiGene

Close